Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSV | O60911 | 2/20 | 0.48 |
| ▸ | CTSL | P07711 | 2/20 | 0.48 |
| ▸ | PTGES | O14684 | 2/20 | 0.48 |
| ▸ | MAPT | P10636 | 2/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | CYP19A1 | P11511 | 5/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | HTR1A | P08908 | 1/20 | 0.44 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.44 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.44 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.44 |
| ▸ | PIN1 | Q13526 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8009518 | 0.89 | MAPT (0.52) | CTSVCTSLMAPTMEN1KMT2A | |
| SCHEMBL14484687 | 0.87 | MAPT (0.51) | CTSVCTSLMAPTMEN1KMT2A | |
| SCHEMBL1137268 | 0.87 | PTGES (0.57) | CTSVCTSLPTGESMAPTMEN1 | |
| SCHEMBL13504298 | 0.87 | CTSV (0.54) | CTSVCTSLPTGESMAPTMEN1 | |
| SCHEMBL810439 | 0.85 | PTGES (0.57) | CTSVCTSLPTGESMAPTMEN1 | |
| SCHEMBL30699715 | 0.85 | PTGES (0.57) | CTSVCTSLPTGESMAPTMEN1 | |
| SCHEMBL31664124 | 0.84 | MEN1 (0.54) | CTSVCTSLMAPTMEN1KMT2A | |
| SCHEMBL21070850 | 0.84 | MEN1 (0.54) | CTSVCTSLMAPTMEN1KMT2A | |
| SCHEMBL6097716 | 0.84 | PTGES (0.54) | CTSVCTSLPTGESMAPTMEN1 | |
| SCHEMBL7426704 | 0.84 | PTGES (0.51) | CTSVCTSLPTGESMAPTMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2046741-B1 | INDOLES AS 5-HT6 MODULATORS | PROXIMAGEN LTD (GB) | 2012-10-31 | — | — | EP | disclosed |
| US-7812017-B2 | 4-substituted indole and indoline compounds | BIOVITRUM AB (PUBL.) (SE) | 2010-10-12 | — | — | US | disclosed |
| CN-101484420-A | Indoles as 5-HT 6 modulators | BIOVITRUM AB PUBL (SE) | 2009-07-15 | — | — | CN | disclosed |
| EP-2046741-A1 | INDOLES AS 5-HT6 MODULATORS | BIOVITRUM AB (publ) (SE) | 2009-04-15 | — | — | EP | disclosed |
| US-20080032968-A1 | New compounds | PROXIMAGEN NEUROSCIENCE PLC (GB) | 2008-02-07 | — | — | US | disclosed |
| WO-2008003703-A1 | INDOLES AS 5-HT6 MODULATORS | BIOVITRUM AB (PUBL) (SE) | 2008-01-10 | — | — | WO | disclosed |
| EP-0505322-B1 | Aminoguanidines | CIBA GEIGY AG (CH) | 1998-09-09 | — | — | EP | disclosed |
| US-5510353-A | TREATING IRRITABLE BOWEL SYNDROME, GASTROESOPHAGEAL REFLUX DISEASE, CONSTIPATION, MIGRAINE HEADACHES | SANDOZ LTD. (CH) | 1996-04-23 | — | — | US | disclosed |
| EP-0505322-A1 | Aminoguanidines | SANDOZ LTD. (CH) | 1992-09-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080032968-A1 | New compounds | HTR6, HTR1B, HTR1A | CTSV 3255/4885CTSL 2336/4885PTGES 679/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.